Polyphenol rich ethanolic extract from Boerhavia diffusa L. mitigates angiotensin II induced cardiac hypertrophy and fibrosis in rats

Prathapan, A.; Varghese, Mathews Valuparampil; Abhilash, S; Raj, P. Salin; Mathew, Anil Kuruvilla; Nair, Anupama; Nair, R. Harikumaran; Raghu, Kozhiparambil Gopalan

doi:10.1016/j.biopha.2016.12.114

Cited by 27 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isorhamnetin, another ingredient of flavonols, ameliorates cardiac hypertrophy and fibrosis induced by aortic banding (Gao et al, 2017 ). Consistent with the results above, Boerhavia diffusa extracted with ethanol (BDE) is a rich source of bioactive flavonols containing quercetin, boeravinone, kaempferol, and caffeic acid, mitigating Ang II-induced cardiac fibrosis via the inhibition of TGF-β1 expression and collagen deposition (Prathapan et al, 2017 ). In recent years, the metabolic effect of rutin and troxerutin have been examined in robust animal models of metabolic syndrome.…”

Section: Anti-fibrotic Effect Of Polyphenols On Cardiac Fibrosismentioning

confidence: 61%

Therapeutic Potential of Polyphenols in Cardiac Fibrosis

Zhang

Wei

et al. 2018

Front. Pharmacol.

View full text Add to dashboard Cite

Cardiac fibrosis, in response to injury and stress, is central to a broad constellation of cardiovascular diseases. Fibrosis decreases myocardial wall compliance due to extracellular matrix (ECM) accumulation, leading to impaired systolic and diastolic function and causing arrhythmogenesis. Although some conventional drugs, such as β-blockers and renin-angiotensin-aldosterone system (RAAS) inhibitors, have been shown to alleviate cardiac fibrosis in clinical trials, these traditional therapies do not tend to target all the fibrosis-associated mechanisms, and do not hamper the progression of cardiac fibrosis in patients with heart failure. Polyphenols are present in vegetables, fruits, and beverages and had been proposed as attenuators of cardiac fibrosis in different models of cardiovascular diseases. Together with results found in the literature, we can show that some polyphenols exert anti-fibrotic and myocardial protective effects by mediating inflammation, oxidative stress, and fibrotic molecular signals. This review considers an overview of the mechanisms of cardiac fibrosis, illustrates their involvement in different animal models of cardiac fibrosis treated with some polyphenols and projects the future direction and therapeutic potential of polyphenols on cardiac fibrosis.

show abstract

Section: Anti-fibrotic Effect Of Polyphenols On Cardiac Fibrosismentioning

confidence: 61%

Therapeutic Potential of Polyphenols in Cardiac Fibrosis

Zhang

Wei

et al. 2018

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…7A, Figure S1). SIRT3 was rst found in the mitochondria of HEK293T cells [43] , and it is highly expressed in tissues and organs with vigorous energy metabolism such as the heart [24,[44][45][46] , which can regulate fatty acid oxidation and tricarboxylic acid cycle to improve energy metabolism disorders [47] . Besides,SIRT3 knockout mice have reduced myocardial energy production, which further impairs cardiac function and metabolism [44] , leading to cardiac remodeling and reduced function [45] .…”

Section: Discussionmentioning

confidence: 99%

Bawei Chenxiang Wan ameliorates right ventricular hypertrophy in rats with high altitude heart disease by SIRT3-HIF1α-PDK/PDH signaling pathway improving fatty acid and glucose metabolism

Han,

Li,

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Bawei Chenxiang Wan (BCW) is among the most effective and widely used therapies for coronary heart disease and angina pectoris in Tibet. However, it is unknown whether it confer protection through right ventricle (RV) myocardial metabolic mechanism. Methods Male Sprague–Dawley rats were oral administration BCW, injected concurrently with a bolus of Sugen5416 (SU5416) and hypoxia exposure (5000m altitude) for 4 weeks(SuHx). Right ventricular hypertrophy (RVH) in high altitude heart disease (HAHD) was assessed using Fulton's index (FI; ratio of RV to left ventricle (LV) +septum weights) and heart weight to body weight ratio (HW/BW). The effect of therapeutic administration of BCW in the RVH on hemodynamics assessed by catheterization [right ventricular and Pulmonary artery pressure (mRVP and mPAP, respectively)]. Tissue samples were used to perform a histological staining, mRNA and protein levels confirmatory analyses to identify altered the mechanisms within the RVH in HAHD. Further verify the protective mechanism of BCW was studied in cell culture. Results BCW significantly reduced SuHx-associated RVH, indicated by macro morphology, HW/BW ratio, Fulton index, mPAP, mRVP, hypertrophy markers, heart function, pathological structure, and the myocardial enzymes. Moreover, BCW can also alleviate the disorder of glucose and fatty acid metabolism by up-regulating carnitine palmitoyltransferase1ɑ (CPT1ɑ), citrate synthase (CS), acetyl-CoA, down-regulating glucose transport-4 (GLUT-4), Phosphofructokinase (PFK), pyruvate, resulting in the reduction of Free fatty acids (FFA), lactic acid (LD) and the increase of aerobic oxidation. This process may be mediated by regulating sirtuin3 (SIRT3)-Hypoxia-inducible factor 1α (HIF1α)-pyruvate dehydrogenase kinase(PDK)/pyruvate dehydrogenase (PDH) signaling pathways. Subsequently, inhibition of SIRT3 expression by 3-TYP (a selective inhibitor of SIRT3) significantly can reverse the anti-RVH in HAHD effect of BCW indicated by hypertrophy markers and serum myocardial enzyme levels. Conclusions In conclusion, BCW prevents SuHx-induced RVH in HAHD by SIRT3-HIF1ɑ-PDK/PDH signaling pathway to alleviate the disturbance in fatty acid and glucose metabolism. Therefore, BCW can be used as an alternative drug for the treatment of RVH in HAHD.

show abstract

“…Cardiac hypertrophy is characterized by reactivation of the fetal gene program, increase in protein synthesis, and subsequent increase in the size of the cardiomyocytes ( Rohini et al, 2010 ; Zhang et al, 2016 ; Prathapan et al, 2017 ). In our study, β-adrenoreceptor agonist ISO by subcutaneous administration was established to cardiac hypertrophy model in vivo and in vitro .…”

Section: Discussionmentioning

confidence: 99%

Bawei Chenxiang Wan Ameliorates Cardiac Hypertrophy by Activating AMPK/PPAR-α Signaling Pathway Improving Energy Metabolism

Zhang

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Bawei Chenxiang Wan (BCW), a well-known traditional Chinese Tibetan medicine formula, is effective for the treatment of acute and chronic cardiovascular diseases. In the present study, we investigated the effect of BCW in cardiac hypertrophy and underlying mechanisms. The dose of 0.2, 0.4, and 0.8 g/kg BCW treated cardiac hypertrophy in SD rat model induced by isoprenaline (ISO). Our results showed that BCW (0.4 g/kg) could repress cardiac hypertrophy, indicated by macro morphology, heart weight to body weight ratio (HW/BW), left ventricle heart weight to body weight ratio (LVW/BW), hypertrophy markers, heart function, pathological structure, cross-sectional area (CSA) of myocardial cells, and the myocardial enzymes. Furthermore, we declared the mechanism of BCW anti-hypertrophy effect was associated with activating adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)/peroxisome proliferator–activated receptor-α (PPAR-α) signals, which regulate carnitine palmitoyltransferase1β (CPT-1β) and glucose transport-4 (GLUT-4) to ameliorate glycolipid metabolism. Moreover, BCW also elevated mitochondrial DNA-encoded genes of NADH dehydrogenase subunit 1(ND1), cytochrome b (Cytb), and mitochondrially encoded cytochrome coxidase I (mt-co1) expression, which was associated with mitochondria function and oxidative phosphorylation. Subsequently, knocking down AMPK by siRNA significantly can reverse the anti-hypertrophy effect of BCW indicated by hypertrophy markers and cell surface of cardiomyocytes. In conclusion, BCW prevents ISO-induced cardiomyocyte hypertrophy by activating AMPK/PPAR-α to alleviate the disturbance in energy metabolism. Therefore, BCW can be used as an alternative drug for the treatment of cardiac hypertrophy.

show abstract

Polyphenol rich ethanolic extract from Boerhavia diffusa L. mitigates angiotensin II induced cardiac hypertrophy and fibrosis in rats

Cited by 27 publications

References 31 publications

Therapeutic Potential of Polyphenols in Cardiac Fibrosis

Therapeutic Potential of Polyphenols in Cardiac Fibrosis

Bawei Chenxiang Wan ameliorates right ventricular hypertrophy in rats with high altitude heart disease by SIRT3-HIF1α-PDK/PDH signaling pathway improving fatty acid and glucose metabolism

Bawei Chenxiang Wan Ameliorates Cardiac Hypertrophy by Activating AMPK/PPAR-α Signaling Pathway Improving Energy Metabolism

Contact Info

Product

Resources

About